The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Aberrant wound-healing responses to injury have been implicated in the development of pulmonary fibrosis, but the mediators directing these pathologic responses have yet to be fully identified. We show that lysophosphatidic acid levels increase in bronchoalveolar lavage fluid following lung injury in the bleomycin model of pulmonary fibrosis, and that mice lacking one of its receptors, LPA1, are markedly protected from fibrosis and mortality in this model. The absence of LPA1 led to reduced fibroblast recruitment and vascular leak, two responses that may be excessive when injury leads to fibrosis rather than to repair, whereas leukocyte recruitment was preserved during the first week after injury. In persons with idiopathic pulmonary fibrosis, lysophosphatidic acid levels in bronchoalveolar lavage fluid were also increased, and inhibition of LPA1 markedly reduced fibroblast responses to the chemotactic activity of this fluid. LPA1 therefore represents a new therapeutic target for diseases in which aberrant responses to injury contribute to fibrosis, such as idiopathic pulmonary fibrosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bexotegrast is a small molecule dual inhibitor of αvβ6 and αvβ1[105]. Cumulative data of 630 patients composed of several phase 1 and 2 trials investigating αvβ6 and αvβ1 in both IPF and primary sclerosing cholangitis demonstrated mild adverse effects in the bexotegrast group (headache, diarrhea, and nausea), with diarrhea being the most common in phase 2 studies”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [104]
In the citing paper
“In pulmonary fi brosis, lysophosphatidic acid receptor 1 (LPA1) activation is associated with fi broblast recruitment, activation/proliferation, and survival, as well as epithelial cell apoptosis, all of which drive lung fi brosis progression (8, 9).”
From Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (2025) · cites this paper as [8]
In the citing paper
“LPA1 is known to be involved in in fl ammatory responses of vascular endothelium and fi broblast recruitment”
From Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (2025) · cites this paper as [8]
In the citing paper
“and LPA1 de fi ciency attenuated fi broblast recruitment in a murine model of lung fi brosis (8).”
From Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (2025) · cites this paper as [8]
Citations
Cites
Wound Healing--Aiming for Perfect Skin Regeneration
Martin, P. (1997) · Science · doi:10.1126/science.276.5309.75 · Cited by 4,804 · cited 1×
“After cutaneous injury, fibroblasts migrate into the provisional fibrin matrix of the wound clot during granulation tissue formatio”
BackgroundRidley, A. J., & Hall, A. (1992) · Cell · doi:10.1016/0092-8674(92)90163-7 · Cited by 4,468
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Chemokines — Chemotactic Cytokines That Mediate Inflammation
Luster, A. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802123380706 · Cited by 3,630 · cited 1×
“1a ), indicating that the relevant fibroblast receptor(s) signal through the Gα i class of G proteins, a hallmark of the chemoattractant subfamily of GPCR”
BackgroundSelf-citationMunger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
The epigenetic progenitor origin of human cancer
Feinberg, A. P., Ohlsson, R., & Henikoff, S. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1748 · Cited by 1,853 · cited 1×
“Epigenetic processes, such as DNA or histone methylation and histone acetylation, produce heritable but potentially reversible changes in DNA or its associated proteins, and are prominent in developmental processes and oncogenesis ( 1 ).”
BackgroundSelman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786 · cited 1×
“In the lung, aberrant wound-healing responses to injury are thought to contribute to the pathogenesis of idiopathic pulmonary fibrosis (IPF”
BackgroundSelf-citationCirculating Fibrocytes Define a New Leukocyte Subpopulation That Mediates Tissue Repair
Bucala, R., Spiegel, L. A., Chesney, J., Hogan, M., & Cerami, A. (1994) · Molecular Medicine · doi:10.1007/bf03403533 · Cited by 1,308
Kim, K. K., Kugler, M. C., Wolters, P. J., Robillard, L., Galvez, M. G., Brumwell, A. N., Sheppard, D., & Chapman, H. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605669103 · Cited by 1,257 · cited 1×
“Fibrin deposition in injured airspaces may contribute to fibroblast accumulation both by providing a provisional matrix for fibroblast migration and by promoting epithelial-to-mesenchymal transitio”
BackgroundThe emerging role of lysophosphatidic acid in cancer
Mills, G. B., & Moolenaar, W. H. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1143 · Cited by 1,094 · cited 1×
“LPA has been shown to induce the invasion of cancer cells across tissue barriers, promoting metastasi”
Background
Cited by
Items 301–400 of 857
Ntatsoulis, K., Karampitsakos, Τ., Tsitoura, E., Stylianaki, E.-A., Matralis, A. N., Tzouvelekis, A., Antoniou, K. M., & Aidinis, V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.687397 · Cited by 45
“More importantly, LPAR1 null mice were reported to be protected from bleomycin (BLM)-induced pulmonary fibrosis, attributed to fibroblast accumulation and reduced vascular leak (68), as well as from Candida albicans water-soluble fraction (CAWS)-induced vasculitis, attributed to reduced CXCL1/IL-8-mediated neutrophil…”
BackgroundResultHuang, L., Qian, W., Xu, Y., Guo, Z., Yin, Y. B., Guo, F., Zhu, W., & Li, Y. Z. (2022) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjac017 · Cited by 44
Self-citationHashimoto, T., Okudaira, S., Igarashi, K., Hama, K., Yatomi, Y., & Aoki, J. (2011) · The Journal of Biochemistry · doi:10.1093/jb/mvr126 · Cited by 41
Cheng, X., Jiang, S., Pan, B., Xie, W., & Meng, J. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01964-3 · Cited by 40
“Another lipid target of interest is LPA1, which has been shown to mediate fibroblast recruitment [147].”
BackgroundZhang, H., Liu, X., Chen, S., Wu, J., Ye, X., Xu, L., Chen, H., Zhang, D., Tan, R. X., & Wang, Y. (2010) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2010.06.022 · Cited by 40
The role of lysophosphatidic acid in the physiology and pathology of the skin
Li, L., Su, J., Chen, J., Chen, W., Chen, X., & Peng, C. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.12.040 · Cited by 44
Gaire, B. P., Lee, C., Kim, W., Sapkota, A., Lee, D. Y., & Choi, J. W. (2020) · Cells · doi:10.3390/cells9081753 · Cited by 41
“Moreover, previous studies showing gene expression levels of LPA receptors have demonstrated that LPA5 is predominantly expressed in alveolar macrophages [45] and tumor-associated macrophages [15].”
BackgroundGrove, L. M., Southern, B. D., Jin, T. H., White, K. E., Paruchuri, S. M., Harel, E., Wei, Y., Rahaman, S. O., Gladson, C. L., Ding, Q., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.498576 · Cited by 40
El‐Asrar, A. M. A., Mohammad, G., Nawaz, M. I., Siddiquei, M. M., Kangave, D., & Opdenakker, G. (2012) · Acta Diabetologica · doi:10.1007/s00592-012-0422-1 · Cited by 40
“increased vascular leakage, increased fibroblast recruitment and proliferation, stimulated macrophage recruitment, and expression of the pro-fibrotic cytokine CTGF [32–35].”
Structure–Activity Relationships of Small Molecule Autotaxin Inhibitors with a Discrete Binding Mode
Miller, L., Keune, W., Castagna, D., Young, L., Duffy, E., Potjewyd, F., Salgado-Polo, F., Garcia, P. E., Semaan, D., Pritchard, J. M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01597 · Cited by 40
Nadhan, R., Nath, K., Basu, S., Isidoro, C., Song, Y. S., & Dhanasekaran, D. N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02423-4 · Cited by 40
SnapShot: Bioactive Lysophospholipids
Moolenaar, W. H., & Hla, T. (2012) · Cell · doi:10.1016/j.cell.2012.01.013 · Cited by 39
Role of autotaxin in cancer stem cells
Lee, D., Suh, D., Lee, S. Ç., Tigyi, G., & Kim, J. H. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-018-9745-x · Cited by 39
“expressed in stromal cells of the lung microenvironment [76].”
Aiello, S., & Casiraghi, F. (2021) · Cells · doi:10.3390/cells10061390 · Cited by 43
“Over the past two decades, a large body of literature has indicated that the ATX/LPA axis plays a pivotal role in the pathogenesis of fibrosis in several organs, including the lung [1,2], kidney [3,4], liver [5] and skin [6].”
BackgroundGPR87 promotes renal tubulointerstitial fibrosis by accelerating glycolysis and mitochondrial injury
Cui, X., Shi, E., Li, J., Li, Y., Qiao, Z., Wang, Z., Liu, M., Tang, W., Sun, Y., Zhang, Y., et al. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.07.004 · Cited by 42
Fakhraee, S. H., Badiee, Z., Mojtahedzadeh, S., Kazemian, M., & Kelishadi, R. (2007) · PubMed · Cited by 48
Ubiquitin E3 ligase FIEL1 regulates fibrotic lung injury through SUMO-E3 ligase PIAS4
Lear, T., McKelvey, A. C., Rajbhandari, S., Dunn, S. R., Coon, T. A., Connelly, W., Zhao, J. Y., Kass, D. J., Zhang, Y., Liu, Y., et al. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20151229 · Cited by 40
“We also tested this pathway in bleomycin-induced murine lung fibrosis (Tager et al., 2008; Jiang et al., 2010).”
Davies, M., Lee, L., Feeley, B. T., Kim, H. T., & Liu, X. (2016) · Journal of Orthopaedic Research® · doi:10.1002/jor.23384 · Cited by 39
Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis
Xie, Y., Jiang, H., Zhang, Q., Mehrotra, S., Abel, P. W., Toews, M. L., Wolff, D. W., Rennard, S. I., Panettieri, R. A., Casale, T. B., et al. (2016) · Respiratory Research · doi:10.1186/s12931-016-0418-4 · Cited by 42
Diverse Functions of Lipids and Lipid Metabolism in Development
Yao, Y., Ding, L., & Huang, X. (2019) · Small Methods · doi:10.1002/smtd.201900564 · Cited by 37
CTHRC1: An Emerging Hallmark of Pathogenic Fibroblasts in Lung Fibrosis
Mukhatayev, Z., Adilbayeva, A., & Kunz, J. (2024) · Cells · doi:10.3390/cells13110946 · Cited by 40
Sun, H., Calle, E. A., Chen, X., Mathur, A., Zhu, Y., Mendez, J. J., Zhao, L., Niklason, L. E., Peng, X., Peng, H., et al. (2013) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00100.2013 · Cited by 40
Riquelme‐Guzmán, C., Contreras, O., & Brandan, E. (2017) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00013.2017 · Cited by 38
Xue, C., Wu, N., Fan, Y., Ma, J., & Ye, Q. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01462-1 · Cited by 37
Platelets in the tumor microenvironment and their biological effects on cancer hallmarks
Chen, L., Zhu, C., Pan, F., Chen, Y., Xiong, L., Li, Y., Chu, X., & Huang, G. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1121401 · Cited by 44
“LPA receptor 1 (LPAR1) expressed in cancer cells is considered as an important response to LPA, and the absence of LPAR1 may affect vascular leak (84, 86, 88, 91).”
BackgroundAl-Hilal, T. A., Chrysovergi, M.-A., Grasberger, P. E., Liu, F., Auernheimer, V., Zhou, Y., Xiao, Z., Duque, M. A. L., Santos, A., Islam, T., et al. (2025) · Nature Cell Biology · doi:10.1038/s41556-025-01697-8 · Cited by 42
“While fibroblast recruitment via chemotaxis is a well-established disease mechanism in tissue fibrogenesis 19,20 , the role of durotaxis remains poorly understood.”
Self-citationRen, Y., Guo, L., Tang, X., Apparsundaram, S., Kitson, C., Deguzman, J., Fuentes, M. E., Coyle, L., Majmudar, R., Allard, J. D., et al. (2012) · Microvascular Research · doi:10.1016/j.mvr.2012.10.004 · Cited by 36
Pharmacometabolic response to pirfenidone in pulmonary fibrosis detected by MALDI-FTICR-MSI
Sun, N., Fernandez, I. E., Wei, M., Witting, M. A., Aichler, M., Feuchtinger, A., Burgstaller, G., Verleden, S. E., Schmitt‐Kopplin, P., Eickelberg, O., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.02314-2017 · Cited by 36
Zulfikar, S., Mulholland, S., Adamali, H. I., & Barratt, S. L. (2020) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s228362 · Cited by 41
Zhao, J., Wei, J., Weathington, N. M., Jacko, A. M., Huang, H., Tsung, A., & Zhao, Y. (2015) · Translational research · doi:10.1016/j.trsl.2015.01.008 · Cited by 38
“Blocking the LPA signal decreases the postinflammatory fibrosis in this bleomycin exposure model, as vascular leak and lung caspase-3 activity were both decreased in LPA1 knockout animals, which also demonstrate a survival advantage in the model.(10) LPA1 knockdown or antagonism with small molecule drugs including the…”
BackgroundNishioka, T., Arima, N., Kano, K., Hama, K., Itai, E., Yukiura, H., Kise, R., Inoue, A., Kim, S. H., Solnica‐Krezel, L., et al. (2016) · Scientific Reports · doi:10.1038/srep23433 · Cited by 36
Self-citationBreath biomarkers in idiopathic pulmonary fibrosis: a systematic review
Hayton, C., Terrington, D. L., Wilson, A. M., Chaudhuri, N., Leonard, C. T., & Fowler, S. J. (2019) · Respiratory Research · doi:10.1186/s12931-019-0971-8 · Cited by 38
Ferreira, B. P., Costa, G., Mascarenhas‐Melo, F., Pires, P. C., Heidarizadeh, F., Giram, P. S., Mazzola, P. G., Cabral, C., Veiga, F., & Paiva‐Santos, A. C. (2023) · Phytochemistry Reviews · doi:10.1007/s11101-023-09860-5 · Cited by 38
Lu, W., Teoh, A. K. Y., Waters, M., Haug, G., Shakeel, I., Hassan, M. I., Shahzad, A. M., Larsson‐Callerfelt, A., Piccari, L., & Sohal, S. S. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108757 · Cited by 37
Development of Lysophosphatidic Acid Pathway Modulators as Therapies for Fibrosis
Budd, D. C., & Qian, Y. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.154 · Cited by 38
Kritikou, E., van Puijvelde, G. H. M., van der Heijden, T., van Santbrink, P. J., Swart, M., Schaftenaar, F. H., Kröner, M. J., Kuiper, J., & Bot, I. (2016) · Scientific Reports · doi:10.1038/srep37585 · Cited by 35
Sakai, N., Bain, G., Furuichi, K., Iwata, Y., Nakamura, M., Hara, A., Kitajima, S., Sagara, A., Miyake, T., Toyama, T., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-43576-x · Cited by 37
Ledein, L., Léger, B., Dees, C., Beyer, C., Distler, A., Vettori, S., Boukaiba, R., Bidouard, J., Schaefer, M., Pernerstorfer, J., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15190 · Cited by 36
“Genetic deletion of Lpar1 blunted bleomycin-induced lung fibrosis (Tager et al., 2008), reduced fibroblast activation and chemotactic activity, and protected from vascular leakage.”
BackgroundYaginuma, S., Omi, J., Kano, K., & Aoki, J. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108415 · Cited by 34
Olianas, M. C., Dedoni, S., & Onali, P. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.04.002 · Cited by 34
An updated patent review of autotaxin inhibitors (2017–present)
Tan, Z., Lei, H., Guo, M., Chen, Y., & Zhai, X. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1867106 · Cited by 34
“Accumulating evidence suggests that downregulation of LPA signaling is effective in various diseases, such as tumor metastasis [3,4], fibrosis [5,6], pruritus[7], multiple sclerosis[8], inflam-”
BackgroundER‐anchored CRTH2 antagonizes collagen biosynthesis and organ fibrosis via binding LARP6
Zuo, S., Wang, B., Liu, J., Kong, D., Cui, H. S., Jia, Y.-N., Wang, C., Xu, X., Chen, G., Wang, Y., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020107403 · Cited by 35
Ali, S. A., Saifi, M. A., Godugu, C., & Talla, V. (2021) · Phytotherapy Research · doi:10.1002/ptr.7210 · Cited by 38
Trials and Treatments: An Update on Pharmacotherapy for Idiopathic Pulmonary Fibrosis
Thong, L., McElduff, E. J., & Henry, M. T. (2023) · Life · doi:10.3390/life13020486 · Cited by 37
“Lysophosphatidic acid receptor-1 (LPA1) has been shown in murine models to regulate fibrosis via mediation of the fibroblast recruitment and vascular leakage on top of being elevated in patients with IPF [86].”
BackgroundMethods for quantifying lysophosphatidic acid in body fluids: A review
Michalczyk, A., Cecerska‐Heryć, E., & Dołęgowska, B. (2014) · Analytical Biochemistry · doi:10.1016/j.ab.2014.02.021 · Cited by 33
“In addition to the physiological LPA functions, several studies have indicated that LPA is implicated in the pathogenesis of many diseases, including atherosclerosis [10], neuropathic pain [11], and hepatic, renal, and pulmonary fibrosis [12–15].”
BackgroundAihara, K., Handa, T., Oga, T., Watanabe, K., Tanizawa, K., Ikezoe, K., Taguchi, Y., Sato, H., Chin, K., Nagai, S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066017 · Cited by 35
“Thus, PGF2a and lysophosphatidic acids, both derived from the breakdown of phospholipids by cPLA2 and possible stimulators of fibrosis [8,33], might act complementarily to affect the progression of disease.”
BackgroundNew therapeutics based on emerging concepts in pulmonary fibrosis
Sontake, V., Gajjala, P. R., Kasam, R. K., & Madala, S. K. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1552262 · Cited by 34
“LPA levels are high in IPF patients’ BAL, acting through receptors LPA1–6 [97].”
BackgroundFibroblasts and their responses to chronic injury in pulmonary fibrosis
Wu, B., Tang, L. F., & Kapoor, M. (2020) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2020.12.003 · Cited by 37
Rebolledo, D. L., Lipson, K. E., & Brandan, E. (2021) · Matrix Biology Plus · doi:10.1016/j.mbplus.2021.100059 · Cited by 33
Emerging Roles of Lysophosphatidic Acid in Macrophages and Inflammatory Diseases
Jiang, S., Yang, H., & Li, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512524 · Cited by 35
Idiopathic Pulmonary Fibrosis: New and Emerging Treatment Options
Hewitt, R. J., & Maher, T. M. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00647-y · Cited by 34
Zhao, J., Wei, J., Dong, S., Bowser, R. K., Zhang, L., Jacko, A. M., & Zhao, Y. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.07.020 · Cited by 33
Discovery of potent inhibitors of the lysophospholipase autotaxin
Shah, P., Cheasty, A., Foxton, C., Raynham, T. M., Farooq, M., Gutierrez, I. F., Lejeune, A., Pritchard, M., Turnbull, A. P., Pang, L., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.10.036 · Cited by 32
Is personalised medicine the key to heterogeneity in idiopathic pulmonary fibrosis?
Clarke, D. L., Murray, L. A., Crestani, B., & Sleeman, M. A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.09.010 · Cited by 32
An outlined review for the role of Nedd4-1 and Nedd4-2 in lung disorders
He, H., Huang, C., Chen, Z., Huang, H., Wang, X., & Chen, J. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109983 · Cited by 32
Fransson, J., Gómez-Conde, A. I., Romero-Imbroda, J., Fernández, Ó., Leyva, L., de Fonseca, F. R., Chun, J. J. M., Louapre, C., Evercooren, A. B., Zujovic, V., et al. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02130-x · Cited by 31
“Lysophosphatidic acid (LPA) is a bioactive phospholipid that influences numerous cell responses, including cell motility, neuropathic pain, inflammation, fibrosis, and cancer (20, 29, 44).”
BackgroundSelf-citationDesign and Development of Autotaxin Inhibitors
Jia, Y., Li, Y., Xu, X., Tian, Y., & Shang, H. (2021) · Pharmaceuticals · doi:10.3390/ph14111203 · Cited by 31
“The LPA signaling pathway is associated with metabolic and inflammatory disorder, and its dysregulation often causes fibrosis [8], liver disease [9], inflammation [10], pruritus [11], metabolic syndrome [12] and cancer [13].”
BackgroundPro-fibrotic activity of lysophosphatidic acid in adipose tissue: In vivo and in vitro evidence
Rancoule, C., Viaud, M., Grès, S., Viguerie, N., Decaunes, P., Bouloumié, A., Langin, D., Bascands, J., Valet, P., & Saulnier‐Blache, J. S. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.10.003 · Cited by 34
Fibrogenic Lung Injury Induces Non–Cell-Autonomous Fibroblast Invasion
Ahluwalia, N., Grasberger, P. E., Mugo, B. M., Feghali‐Bostwick, C. A., Pardo, A., Selman, M., Lagares, D., & Tager, A. M. (2015) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2015-0040oc · Cited by 33
“We have previously demonstrated that the fibroblast chemoattractant activity of IPF BAL is largely attributable to lysophosphatidic acid (LPA) that is induced by lung injury (12).”
BackgroundSelf-citationA new era in the treatment of progressive fibrosing interstitial lung diseases
Denis, A., Tsiri, P., Guiot, J., & Τzouvelekis, Α. (2025) · Breathe · doi:10.1183/20734735.0259-2024 · Cited by 37
“In mice models with bleomycin-induced fibrosis, bronchoalveolar lung fluid showed increased levels of LPA, while LPA1 receptor knockout protected them from fibrosis by reducing fibroblast recruitment and vascular leak [37].”
Epithelial Responses to Lung Injury: Role of the Extracellular Matrix
Chapman, H. A. (2012) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201112-053aw · Cited by 30
Hong, D., Zhang, G., Zhang, X., & Liang, X. (2016) · Medicine · doi:10.1097/md.0000000000003008 · Cited by 35
“A previous study reported that the concentration of LPA in broncho-alveolar lavage (BAL) fluid of patients with IPF was clearly, obviously higher than that of healthy controls.(45) In a bleomycin mouse model of pulmonary fibrosis, the concentration of LPA in BAL fluid markedly increased after 5 days,(45) and LPA1-defi…”
ResultLu, Y., Zhao, X., Yu, L., Qi, F., Zhai, B., Gao, C., & Ding, Q. (2017) · Scientific Reports · doi:10.1038/srep46357 · Cited by 31
Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction
Juillerat‐Jeanneret, L., Aubert, J., Mikulic, J., & Golshayan, D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00294 · Cited by 30
“PAT-1251 (58) was identified as a potent, highly selective, irreversible batimastat (49) marimastat (50) PG-116800 (51)”
BackgroundPatel, R. B., Kotha, S. R., Sherwani, S. I., Sliman, S. M., Gurney, T. O., Loar, B., Butler, S. O., Morris, A. J., Marsh, C. B., & Parinandi, N. L. (2010) · International Journal of Toxicology · doi:10.1177/1091581810388850 · Cited by 31
“The role of LPA receptor 1 linking pulmonary fibrosis to lung injury toward causing fibroblast recruitment and vascular leak in the bleomycin mouse model of pulmonary fibrosis has been unequivocally elucidated.(62) Nevertheless, the sources of LPA in these studies have not been identified at least in the bleomycin pul…”
BackgroundDecrease in circulating autotaxin by oral administration of prednisolone
Sumida, H., Nakamura, K., Yanagida, K., Ohkawa, R., Asano, Y., Kadono, T., Tamaki, K., Igarashi, K., Aoki, J., Sato, S., et al. (2012) · Clinica Chimica Acta · doi:10.1016/j.cca.2012.10.003 · Cited by 30
HSP27 regulates TGF-β mediated lung fibroblast differentiation through the Smad3 and ERK pathways
Wang, G., Jiao, H., Zheng, J., & Sun, X. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2813 · Cited by 31
“Additionally, TGF-β is also involved in a crosstalk with wnt/ β -catenin, sphingosine 1 phospate, lysophosphatidic acid and NF-κ B pathways to induce pro-or anti-fibrotic gene expression during pulmonary fibro-genesis (5,14,15,32,33).”
LPA receptor 4 deficiency attenuates experimental atherosclerosis
Yang, L., Kraemer, M. P., Fang, X., Angel, P. M., Drake, R. R., Morris, A. J., & Smyth, S. S. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m091066 · Cited by 30
“In addition to its effects on endothelial cells (13, 14) and SMCs (6, 7), LPA is a weak activator of platelets (9, 10) and a potent stimulus for fibronectin matrix assembly (15).”
BackgroundLey, K. F., & Zarbock, A. (2008) · Nature Medicine · doi:10.1038/nm0108-20 · Cited by 34
Jaiswal, A. K., Rehman, R., Dutta, J., Singh, S., Ray, A., Shridhar, M., Jaisankar, J., Bhatt, M., Khandelwal, D., Sahoo, B., et al. (2023) · Cells · doi:10.3390/cells12071044 · Cited by 29
Dong, Y., Duan, X., Liu, Y.-J., Fan, H., Xu, M., Chen, Q.-Y., Nan, Z., Wu, H., & Deng, S. (2019) · Inflammation · doi:10.1007/s10753-019-01015-z · Cited by 30
Rodríguez‐Rodríguez, A., Shuvaev, S., Rotile, N. J., Jones, C. M., Probst, C. K., Ferreira, D. S., Graham‐O'Regan, K. A., Boros, E., Knipe, R. S., Griffith, J. W., et al. (2019) · ACS Sensors · doi:10.1021/acssensors.9b01010 · Cited by 29
Self-citationInhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone
Ma, H., Heiden, J. A. V., Uttarwar, S., Xi, Y., N’Diaye, E.-N., LaCanna, R., Caplazi, P., Gierke, S., Moffat, J. G., Wolters, P. J., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.00604-2022 · Cited by 30
Knipe, R. S., Nurunnabi, M., Probst, C. K., Spinney, J. J., Abe, E. A., Bose, R. J., Ha, K., Logue, A., Nguyen, T. H., Servis, R. L., et al. (2023) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00086.2022 · Cited by 29
Heparan Sulfate Proteoglycans Mediate Factor XIIa Binding to the Cell Surface
Wujak, L. A., Didiášová, M., Zakrzewicz, D., Frey, H., Schaefer, L., & Wygrecka, M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.606343 · Cited by 30
Murray, L. A., Rubinowitz, A. N., & Herzog, E. L. (2012) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3283588de4 · Cited by 33
David, M., Sahay, D., Mege, F., Descôtes, F., Leblanc, R., Ribeiro, J., Clézardin, P., & Peyruchaud, O. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097771 · Cited by 29
Evolution and treatment of idiopathic pulmonary fibrosis
Torrisi, S. E., Kahn, N. C., Vancheri, C., & Kreuter, M. (2020) · La Presse Médicale · doi:10.1016/j.lpm.2020.104025 · Cited by 29
Lysophosphatidic Acid Signalling in Nervous System Development and Function
Birgbauer, E. (2020) · NeuroMolecular Medicine · doi:10.1007/s12017-020-08630-2 · Cited by 29
Structure–function relationships of autotaxin, a secreted lysophospholipase D
Hausmann, J., Anastassis Perrakis, A., & Moolenaar, W. H. (2012) · Advances in Biological Regulation · doi:10.1016/j.jbior.2012.09.010 · Cited by 29
Idiopathic pulmonary fibrosis: the turning point is now!
Funke, M., & Geiser, T. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14139 · Cited by 38
Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis
Volkmann, E. R., Denton, C. P., Kolb, M. R. J., Wijsenbeek-Lourens, M. S., Emson, C. L., Hudson, K. J., Amatucci, A. J., Distler, O., Allanore, Y., & Khanna, D. (2024) · European Respiratory Review · doi:10.1183/16000617.0015-2024 · Cited by 29
Novel Inhibitory Effect of a Lysophosphatidic Acid 2 Agonist on Allergen-Driven Airway Inflammation
Knowlden, S. A., Hillman, S. E., Chapman, T. J., Patil, R., Miller, D. D., Tigyi, G., & Georas, S. N. (2015) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2015-0124oc · Cited by 28
“In addition to dendritic cells, LPA2 is expressed on mouse CD41 (35, 36) and CD81 (36) T cells, neutrophils (36), lung endothelial cells (36), fibroblasts (36), and tracheal epithelial cells (34).”
BackgroundInfluentialTsukui, T., Ueha, S., Shichino, S., Inagaki, Y., & Matsushima, K. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.07.022 · Cited by 30
Aptamers as therapeutic middle molecules
Nakamura, Y. (2017) · Biochimie · doi:10.1016/j.biochi.2017.10.006 · Cited by 28
Deng, Q., Zhang, J., Yj, G., She, X., Wang, Y., Wang, Y., & Ge, X. (2017) · PubMed · Cited by 28
Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders
Sofias, A. M., Lorenzi, F. D., Peña, Q., Shalmani, A. A., Vucur, M., Wang, J., Kiessling, F. M., Shi, Y., Consolino, L., Storm, G., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113831 · Cited by 28
“Although not involved in myofibroblast activation, it was observed that LPA induced chemotaxis of lung fibroblasts in bleomycin-induced lung fibrosis, with consequent collagen increase [216].”
BackgroundTargeting lysophospholipid acid receptor 1 and ROCK kinases promotes antiviral innate immunity
Zhang, C., Li, W., Lei, X., Xie, Z., Qi, L., Wang, H., Xiao, X., Xiao, J., Zheng, Y., Dong, C., et al. (2021) · Science Advances · doi:10.1126/sciadv.abb5933 · Cited by 31
Lipids and eicosanoids in fibrosis: emerging targets for therapy
Castelino, F. V. (2012) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328356d9f6 · Cited by 30
“In addition, inhibition of LPA1 results in attenuated lung fibroblast recruitment [5].”
BackgroundJang, H. J., Lee, D. Y., Loloci, G., Jeong, J., & Choi, W.-I. (2023) · European Respiratory Journal · doi:10.1183/13993003.00291-2023 · Cited by 28
Unconjugated bilirubin is associated with protection from early-life wheeze and childhood asthma
Turi, K. N., McKennan, C. G., Gebretsadik, T. S., Snyder, B. M., Seroogy, C. M., Lemanske, R. F., Zoratti, E. M., Havstad, S. L., Ober, C., Lynch, S. V., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.12.639 · Cited by 27
“4 3 10(217)} Did not graduate high school (HS) 31 (9) 0 (0) 0 (0) 3 (2) Graduated HS, but no college 76 (22) 13 (9) 4 (6) 7 (6) Attended college, but did not graduate 87 (26) 13 (9) 12 (18) 21 (17) Graduated college 144 (43) 113 (78) 49 (73) 95 (75) Missing 0 (0) 6 (4) 2 (3) 1 (1) Sex {P 5 .”
Gallardo, F. S., Córdova-Casanova, A., & Brandan, E. (2021) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-021-00610-w · Cited by 29
Plasma Metabolic Profiling in Patients With Silicosis and Asbestosis
Zhou, M., Xue, C., Fan, Y., Wu, N., Ma, J., & Ye, Q. (2021) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0000000000002232 · Cited by 27
“Lysophosphatidic acid (LPA) is produced by activated platelets and fibroblasts and was increased in damaged skin and fibrotic lung in various fibrosis models.(28) The hydrolysis of lysophosphatidylcholine by lysophospholipase D/ autotaxin represents one pathway for LPA synthesis.”
BackgroundFunke-Chambour, M., Knudsen, L., Lagares, D., Ebener, S., Probst, C. K., Fontaine, B. A., Franklin, A., Kellner, M., Kühnel, M., Matthieu, S., et al. (2016) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2015-0152oc · Cited by 27
“We have previously implicated LPA–LPA1 signaling in the development of fibrosis in multiple organs, including the lung (6, 42), the skin (43), and the peritoneum (44), whereas others have implicated this pathway in renal and hepatic fibrosis (45, 46).”
BackgroundMethodResultSelf-citationβ-Arrestins in the Immune System
Jiang, D., Xie, T., Liang, J., & Noble, P. W. (2013) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-394440-5.00014-0 · Cited by 30
Terakado, M., Suzuki, H., Hashimura, K., Tanaka, M., Ueda, H., Kohno, H., Fujimoto, T., Saga, H., Nakade, S., Habashita, H., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00225 · Cited by 27
González-Gil, I., Zian, D., Vázquez‐Villa, H., Hernández‐Torres, G., Martínez, R. F., Khiar‐Fernández, N., Rivera, R. R., Kihara, Y., Devesa, I., Mathivanan, S., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01287 · Cited by 31
Self-citationTaketomi, Y., Higashi, T., Kano, K., Miki, Y., Mochizuki, C., Toyoshima, S., Okayama, Y., Nishito, Y., Nakae, S., Tanaka, S., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.06.012 · Cited by 27
Self-citationEmerging therapies for the treatment of systemic sclerosis
Distler, J. H. W., Kuwana, M., Assassi, S., & Denton, C. P. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01294-x · Cited by 29
“LPA is part of the tissue injury response that can promote inflammation and scarring and evidence suggests that LPA is a mediator of bleomycin-induced lung fibrosis 24 .”
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis
Aryal, S., & Nathan, S. D. (2018) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2018.1471465 · Cited by 29
“Lysophosphatidic acid (LPA) is a pleiotropic lipid molecule with potent cellular effects including fibroblast recruitment and survival, as well as epithelial apoptosis and endothelial damage [82].”
Background
Metadata
- Authors
- Tager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., Hart, W. K., Pardo, A., Blackwell, T. S., Xu, Y., Chun, J., & Luster, A. D.
- Affiliations
- Harvard University (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Indiana University Indianapolis (US)
- Vanderbilt University (US)
- Universidad Nacional Autónoma de México (MX)
- Scripps Research Institute (US)
- Corresponding author
- Luster, Andrew D
- ORCID
- Venue
- Nature Medicine
- Published
- 2007-12-09
- Volume
- 14
- Issue
- 1
- Pages
- 45-54
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2131032222
- Cited by
- 823
- References
- 54
- Citations by year
- 2026: 24 · 2025: 49 · 2024: 50 · 2023: 49 · 2022: 51 · 2021: 61 · 2020: 55 · 2019: 38 · 2018: 36 · 2017: 47 · 2016: 49 · 2015: 41 · 2014: 51 · 2013: 49 · 2012: 53
- FWCI
- 23.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Lung Association
- National Institutes of Health (5r01ca069212-18)
- National Institute of Mental Health (K02 MH01723, R01MH051699, K02MH001723, R01MH-51699)
- National Cancer Institute (R01CA69212, R01-CA89228, R01CA095042, R01CA089228)
- National Institute of Neurological Disorders and Stroke (R01NS048478)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- lysophosphatidic acid, LPA1 receptor, pulmonary fibrosis, idiopathic pulmonary fibrosis, lung injury, fibroblast recruitment, vascular leakage, bleomycin-induced fibrosis, bronchoalveolar lavage fluid, wound healing, chemotaxis, therapeutic target
- MeSH terms
- Animals, Bleomycin, Bronchoalveolar Lavage Fluid, Female, Fibroblasts, Leukocytes, Lung, Lysophospholipids, Male, Mice, Inbred C57BL, Models, Biological, Pulmonary Fibrosis, Mice, Knockout, Receptors, Lysophosphatidic Acid, Mice, Lung Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.